Document Detail

The potential role of fowlpox virus in rational vaccine design.
MedLine Citation:
PMID:  16989636     Owner:  NLM     Status:  MEDLINE    
The design of optimal vaccines requires detailed knowledge of how protective immune responses are generated in vivo under normal circumstances. This approach to vaccine development, where the immune correlates of protection are defined and vaccines are designed to elicit the same response, is called rational vaccine design. Poxviruses are attractive candidates for inclusion in such design strategies owing to their large genome, which allows for the inclusion of multiple heterologous genes, including those encoding antigens, co-stimulatory molecules and cytokines. Fowlpox virus, the prototypical member of the Avipoxvirus genus, is particularly suitable, as it is also incapable of replicating in mammalian cells. The potential of recombinant fowlpox virus as a safe vaccine vector is being evaluated currently in a number of clinical trials for diseases, including HIV, malaria and various types of cancer. Despite their promise, intricate details regarding how fowlpox virus interacts with the host immune system have not been resolved. In this review, the issues surrounding the use of fowlpox virus as a vaccine vector and possible strategies for enhancing its efficacy are discussed.
Emma L Beukema; Michael P Brown; John D Hayball
Related Documents :
16087046 - Nmr assays for carbohydrate-based vaccines.
2696166 - Immunoprophylactic control of bovine babesiosis: role of exoantigens of babesia.
18398296 - Protective immunity following vaccination: how is it defined?
12139306 - Proteomics approaches towards antigen discovery and vaccine development.
23446216 - Linkage between anaplasma marginale outer membrane proteins enhances immunogenicity but...
2842446 - Systemic lymphoproliferative responses to rotavirus.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert review of vaccines     Volume:  5     ISSN:  1744-8395     ISO Abbreviation:  Expert Rev Vaccines     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-09-22     Completed Date:  2006-10-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101155475     Medline TA:  Expert Rev Vaccines     Country:  England    
Other Details:
Languages:  eng     Pagination:  565-77     Citation Subset:  IM    
Experimental Therapeutics Laboratory, Hanson Institute, Level 4, Hanson Institute Building, Frome Road, Adelaide, South Australia, 5000, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
AIDS Vaccines
Cancer Vaccines
Clinical Trials as Topic
Drug Design
Fowlpox virus / immunology*
HIV Infections / immunology*
Malaria / immunology
Neoplasms / immunology
Poxviridae / classification
Vaccines, Synthetic*
Viral Vaccines*
Reg. No./Substance:
0/AIDS Vaccines; 0/Cancer Vaccines; 0/Vaccines, Synthetic; 0/Viral Vaccines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pneumococcal conjugate vaccines: emerging clinical information and its implications.
Next Document:  Kinetic diversity in G-protein-coupled receptor signalling.